| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.08 | 0.08 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.08 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.09 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.09 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.09 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |